Institutional Fund
Squadron Capital Management LLC
Westmont, ILCIK 20507092 filings on record
Portfolio Value
$249.96M
Q1 2026
Holdings
30
Reported positions
New Buys
13
Opened this quarter
QoQ Change
+11.5%
from $224.10M
Portfolio Value Trend
Reported 13F value by quarter
Portfolio value trend — upgrade to see history
UpgradeTop Allocations
Largest positions by weight
- Relmada Therapeutics Inc23.6%
- Cogent Biosciences Inc12.1%
- Kalvista Pharmaceuticals Inc7.9%
- Kodiak Sciences Inc5.8%
- Abivax SA5.8%
- Edgewise Therapeutics Inc4.4%
- Other40.3%
Portfolio Holdings
30 positions · Q1 2026
| # | Security | Shares | Value | % Port. | Δ Shares | Activity |
|---|---|---|---|---|---|---|
| 1 | Relmada Therapeutics Inc | 8.47M | $58.98M | 23.6% | +1.77M | Added |
| 2 | Cogent Biosciences Inc | 787.5K | $30.31M | 12.1% | +7.5K | Added |
| 3 | Kalvista Pharmaceuticals Inc | 985.1K | $19.83M | 7.9% | +285.1K | Added |
| 4 | Kodiak Sciences Inc | 380.0K | $14.49M | 5.8% | +88.3K | Added |
| 5 | Abivax SA | 130.0K | $14.48M | 5.8% | −15.0K | Reduced |
| 6 | Edgewise Therapeutics Inc | 350.0K | $11.03M | 4.4% | 0 | Held |
| 7 | Nektar Therapeutics | 125.0K | $8.99M | 3.6% | +125.0K | New |
| 8 | Adlai Nortye Ltd | 1.27M | $8.76M | 3.5% | +1.27M | New |
| 9 | Zentalis Pharmaceuticals Inc | 3.63M | $8.50M | 3.4% | +3.63M | New |
| 10 | Maze Therapeutics Inc | 257.5K | $7.69M | 3.1% | −232.5K | Reduced |
20 more holdings on Premium
See this fund's complete portfolio, full position changes, and activity history.
Unlock full portfolio